Literature DB >> 6623096

Neutrophil activation as a mechanism of tissue injury.

H S Jacob.   

Abstract

C5A is capable of causing granulocyte/granulocyte interactions that lead to clumping, vasoocclusion, and the extension of infarctive damage in patients with coronary artery disease. Employing a new rheologic procedure, laser transillumination of thin vascular beds, one directly observes in vivo granulocyte aggregation in the mesentery of the rat. Nonsteroidal antiinflammatory drugs (NSAIDs) were shown to stop granulocyte agglomeration and to limit the extension of experimental myocardial infarcts in the cat. There may be application for NSAIDs for myocardial infarction in humans. NSAIDs block granulocyte aggregation to both a traditional activated complement and a complement activated by cryoglobulins. Patients with severe cryoglobulinemic cutaneous vasculitis who failed on steroids responded to NSAID administration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6623096     DOI: 10.1016/0049-0172(83)90034-3

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  3 in total

1.  A novel assay for neutrophil clustering activity of human sera: relation to disease activity and neutropenia in systemic lupus erythematosus.

Authors:  H Jonsson; G Sturfelt
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

2.  Evaluation of disease activity in rheumatic patients by leucocyte adhesiveness/aggregation.

Authors:  S Berliner; M Fried; D Caspi; A Weinberger; M Yaron; J Pinkhas; M Aronson
Journal:  Ann Rheum Dis       Date:  1988-06       Impact factor: 19.103

3.  Severe acute respiratory Syndrome-Coronavirus-2: Can it be detected in the retina?

Authors:  Tarek Bayyoud; Angelika Iftner; Thomas Iftner; Karl Ulrich Bartz-Schmidt; Focke Ziemssen; Hans Bösmüller; Falko Fend; Jens Martin Rohrbach; Marius Ueffing; Michael Schindler; Sebastian Thaler
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.